There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TRAIL R1


Brief Information

Name:Tumor necrosis factor receptor superfamily member 10A
Target Synonym:TRAIL-R1,Tumor necrosis factor receptor superfamily member 10A,DR4,TRAILR1,APO2,TNFRSF10A,TNF Receptor Superfamily Member 10a,Tumor Necrosis Factor Receptor Superfamily, Member 10a,Death Receptor 4,TRAIL Receptor 1,Cytotoxic TRAIL Receptor,CD261 Antigen,T
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TR1-H5254 Human Human TRAIL R1 / DR4 / TNFRSF10A Protein, Fc Tag
TR1-H5228 Human Human TRAIL R1 / DR4 / TNFRSF10A Protein, His Tag

Part of Bioactivity data


Loaded Human TRAIL R1, Fc Tag (Cat. No. TR1-H5254) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.891 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human TRAIL, His Tag on HIS1K Biosensor, can bind Human TRAIL R1, Fc Tag (Cat. No. TR1-H5254) with an affinity constant of 2.4 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name



Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) is also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TRAILR1 / TNFRSF10A contains 1 death domain and 3 TNFR-Cys repeats. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAILR-1 / DR4 / CD261 promotes the activation of NF-kappa-B.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
HLX56 HLX56; HLX-56 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Solid tumours Details
Eftozanermin alfa APG-350; APG-880; ABBV-621; PR-1625011 Phase 1 Clinical Abbvie Inc Hematologic Neoplasms; Multiple Myeloma Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) Phase 3 Clinical Shenzhen Xinpeng Biology Engineering Co Ltd Neoplasms Details
Circularly permuted TRAIL (Beijing Sunbio Biotech) Phase 3 Clinical Beijing Shadong Biotech Co Ltd Multiple Myeloma Details
Dulanermin (Shanghai GeBaiDe) Phase 3 Clinical Shanghai Gebaide Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details
Mapatumumab TRAIL-R1; DR4-mAB; HGS-1012; HGS-ETR1; TRM-1 Phase 2 Clinical Cambridge Antibody Technology Liver Neoplasms; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details

This web search service is supported by Google Inc.